Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003.
BACKGROUND
Transfusion-transmitted West Nile virus (WNV) infections were first reported in 2002, which led to rapid development of investigational nucleic acid amplification tests (NAT). A study was conducted to evaluate sensitivities of WNV screening and supplemental NAT assays first employed in 2003.


METHODS
Twenty-five member-coded panels were distributed to NAT assay manufacturers. Panels included five pedigreed WNV standards (1, 3, 10, 30, and 100 copies/mL), 15 or 16 donor units with very-low-level viremia identified through 2003 screening, and four or five negative control samples. Samples were tested neat in 10 replicates by all assays; for NAT screening assays, 10 replicates were also performed on dilutions consistent with minipool (MP)-NAT. The viral load distribution for 142 MP-NAT yield donations was characterized, relative to the analytical sensitivity of MP-NAT systems.


RESULTS
Analytical sensitivities (50% limits of detection [LoD] based on Poisson model of detection of WNV standards) for screening NAT assays ranged from 3.4 to 29 copies per mL; when diluted consistent with MP pool sizes, the 50 percent LoD of screening NAT assays was reduced to 43 to 309 copies per mL. Analytical sensitivity of supplemental assays ranged from 1.5 to 7.7 copies per mL (50% LoD). Detection of RNA in donor units varied consistent with analytical LoD of assays. Detection of low-level viremia after MP dilutions was particularly compromised for seropositive units, probably reflecting lower viral loads in the postseroconversion phase. Based on the viral load distribution of MP-NAT yield donations (median, 3519 copies/mL; range, < 50-690,000), 13 to 24 percent of units had viral loads below the 50 percent LoD of screening NAT assays run in MP-NAT format.


CONCLUSIONS
WNV screening and supplemental assays had generally excellent analytical sensitivity, comparable to human immunodeficiency virus-1 and hepatitis C virus NAT assays. The presence of low-level viremic units during epidemic periods and the impact of MP dilutions on sensitivity, however, suggest the need for further improvements in sensitivity as well as a role for targeted individual-donation NAT in epidemic regions.
Busch
M P
MP
Blood Systems Research Institute, San Francisco, California, USA. mpbusch@itsa.ucsf.edu
Tobler
L H
LH
Saldanha
J
J
Caglioti
S
S
Shyamala
V
V
Linnen
J M
JM
Gallarda
J
J
Phelps
B
B
Smith
R I F
RI
Drebot
M
M
Kleinman
S H
SH
D001771:Blood Banks; D002170:Canada; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D012367:RNA, Viral / Q000032:analysis; D012680:Sensitivity and Specificity; D014481:United States; D019562:Viral Load; D014766:Viremia / Q000097:blood / Q000175:diagnosis; D014901:West Nile Fever / Q000097:blood* / Q000175:diagnosis*; D014902:West Nile virus / Q000235:genetics* / Q000302:isolation & purification*
D012367:RNA, Viral